MedTrace Logo

Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00972140 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 457

Last updated 2011-12-13

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the clinical equivalence of formoterol-HFA pMDI 12µg/actuation administered twice daily to formoterol DPI 12µg/capsule delivered by the Aerolizer inhaler and administered twice daily in patients with COPD.

Conditions

Interventions

DRUG

Formoterol

Formoterol-HFA pMDI 12µg twice daily

DRUG

Formoterol

Formoterol-DPI 12 µg twice daily

Sponsors & Collaborators

  • Chiesi Farmaceutici S.p.A.

    lead INDUSTRY

Principal Investigators

  • Iwona Graelewska Rzymowska, Prof · Clinic Pneumology and Allergology Lodz Poland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2006-04-30
Completion
2006-10-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00972140 on ClinicalTrials.gov